Valuation: Profound Medical Corp.

Market Cap 325M 229M 201M 185M 173M 21.62B 331M 2.23B 862M 10.66B 861M 842M 37.04B P/E 2026 *
-7.72x
P/E 2027 * -8.67x
Enterprise Value 325M 229M 201M 185M 173M 21.62B 331M 2.23B 862M 10.66B 861M 842M 37.04B EV / Sales 2026 *
9.09x
EV / Sales 2027 * 5.36x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day-3.97%
1 week-7.16%
Current month-6.09%
1 month-10.50%
3 months+11.32%
6 months-12.68%
Current year-16.90%
1 week 8.95
Extreme 8.95
9.77
1 month 8.83
Extreme 8.83
9.78
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
17.7
5 years 4.21
Extreme 4.21
22.75
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
President 44 2024-11-06
Director of Finance/CFO 58 2022-03-02
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Date Insider Type Main position Quantity % Market Cap.
06-16Option

Chief Financial Officer

7,745 0.0213%
06-16Option

Executive/Senior Manager

10,545 0.0290%
06-16Option

Chief Executive Officer

70,350 0.1936%
Change 5-day change 1-year change 3-year change Capi.($)
-3.97%-7.16%+6.29%-47.66% 238M
+2.75%+8.85%+23.16%-3.52% 183B
-0.53%-1.74%-23.38%+22.13% 142B
+2.30%+9.05%-3.88%-18.88% 134B
-0.58%-2.41%-57.62%-18.10% 66.08B
+0.07%+2.70%+16.56%-0.69% 51.63B
+0.50%-0.09%-26.76%-32.86% 43.38B
+2.95%+6.65%+14.24%+13.47% 37.18B
+2.09%+6.03%+7.68%+45.05% 36.25B
+0.09%+5.44%-10.74%-18.64% 29.51B
Average +0.74%+2.66%-5.44%-5.97% 72.32B
Weighted average by Cap. +1.46%+3.20%-4.47%-1.53%

Financials

2026 *2027 *
Net sales 35.76M 25.2M 22.13M 20.39M 19.07M 2.38B 36.42M 245M 94.76M 1.17B 94.62M 92.54M 4.07B 60.68M 42.76M 37.56M 34.6M 32.35M 4.03B 61.79M 415M 161M 1.99B 161M 157M 6.91B
Net income -43.31M -30.52M -26.8M -24.7M -23.09M -2.88B -44.1M -296M -115M -1.42B -115M -112M -4.93B -40.7M -28.68M -25.19M -23.21M -21.7M -2.71B -41.45M -278M -108M -1.33B -108M -105M -4.64B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26-06-25 $8.950 -3.97% 15,226
26-06-24 $9.320 -0.53% 501
26-06-23 $9.370 +0.43% 4,852
26-06-22 $9.330 -2.81% 28,720
26-06-19 $9.600 -0.41% 2,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.950
Average target price
-

Quarterly revenue - Rate of surprise